<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477138</url>
  </required_header>
  <id_info>
    <org_study_id>VOTEPM</org_study_id>
    <nct_id>NCT01477138</nct_id>
  </id_info>
  <brief_title>RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome</brief_title>
  <acronym>VOTE</acronym>
  <official_title>Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Nürnberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Nürnberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Potential negative effects of pacing in the RV-apex are well documented

        -  However, study results comparing septal / RVOT-pacing versus RV-apical pacing
           controversial.

        -  The optimal pacing mode in SSS (DDDR versus AAIR) is unclear, as the DDD (R) mode with
           an AV delay ≤ 220 ms should be the preferred pacing mode, according to the DANPACE trial
           [DANPACE, ESC 2010, Stockholm].

      Aim:

      - to evaluate chronic effects of proven right ventricular septal compared to minimized right
      ventricular septal pacing in patients with SSS

      Inclusion criterion:

      -Pacemaker indication according to current guidelines: sick sinus syndrome (SSS)

      Exclusion criteria:

        -  Life expectancy &lt; 2 years

        -  Age &lt;18 years

        -  Noncompliance with regard to participation in the study

        -  Pregnancy

        -  AV block ° 2 and higher

        -  Permanent atrial fibrillation

        -  Heart failure NYHA III and IV, reduced LV-EF &lt;40%

        -  ICD indication

        -  Acute coronary syndrome. PCI or CABG &lt;3 months

        -  Heart transplant

        -  Placement of septal RV electrode is not possible

      Study design:

        -  Prospective, monocentric, randomized, double-blinded

        -  Run-in phase: for weeks AAI [R]-DDD [R]

        -  Randomization: two groups A) septal right ventricular chamber pacing: mode DDD [R]
           versus B) Reduction of unnecessary ventricular pacing: AAI [R]-DDD [R].

        -  FU: 6 and 12-months

      Primary endpoints:

      -LV ejection fraction and end-systolic LV volume after 12 months.

      Secondary endpoints:

      -LV end-diastolic volume, TAPSE, parameters of dyssynchrony (SPWMD, LV-PEP, IVMD), AF-burden,
      % ventricular pacing, CPX: peak oxygen consumption (peak VO2), VO2 AT, VO2/HR, VE/VCO2 slope;
      QoL scores (SF-36) after 12 months.

      Statistics/sample size estimation:

      In order to detect a difference in LVEF of 5% and for LV-ESV of 5 mL between the 2 groups
      after 12 months:

        -  90% power/alpha 5%: 84 patients per group

        -  80% power/alpha 5%: 63 patients per group

             -  10% for compensation of drop-outs / patients lost of follow-up. Two-sided 5% type 1
                error Analysis intention-to-treat and based on the finally programmed pacing mode.

      Material

        -  PG: market released dual chamber pacemakers with the ability to pace AAI(R) -DDD(R)

        -  pacing leads: market-released standard active electrodes

        -  RV electrode: septal verified under multi-level screening (RAO/LAO) and ECG (LBBB narrow
           &lt;150 ms / inferior axis)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Potential negative effects of pacing in the RV-apex are well documented

        -  Asynchronous ventricular activation

        -  reduction of systolic and diastolic LV function

        -  Experimental data: histological changes

        -  Asymmetric LV hypertrophy and thinning

        -  However, study results comparing septal / RVOT-pacing versus RV-apical pacing
           controversial:

        -  Acute versus chronic

        -  Small number of cases, uncontrolled, unblinded,

        -  Brief periods of observation in the cross-over design (3 months)

        -  &quot;RVOT&quot; often summarizes different stimulation sites: high RVOT, lateral, septal.
           Actually only limited data with proven septal stimulation

        -  No objective performance assessment (CPX)

        -  Assessment of alternative stimulation site previously RVOT versus RV-apex,

        -  ventricular pacing compared to ventricular pacing, then tested a potential harm to
           another

        -  The question of the optimal pacing mode of patients with SSS (DDDR versus AAIR) appears
           to be open again. While in Germany, two-chamber systems with AAI [R] mode with
           ventricular back-up are used, should the DDD (R) mode with an AV delay ≤ 220 ms be the
           preferred pacing mode, according to the results of the DANPACE trial for patients with
           SSS [DANPACE, ESC 2010, Stockholm].

      Aim:

      - to evaluate chronic effects of proven right ventricular septal compared to minimized right
      ventricular septal pacing in patients with SSS

      Inclusion criterion:

      -Pacemaker indication according to current guidelines: sick sinus syndrome (SSS)

      Exclusion criteria:

        -  Life expectancy &lt; 2 years

        -  Age &lt;18 years

        -  Noncompliance with regard to participation in the study

        -  Pregnancy

        -  AV block ° 2 and higher

        -  Permanent atrial fibrillation

        -  Heart failure NYHA III and IV, reduced LV-EF &lt;40%

        -  ICD indication

        -  Acute coronary syndrome. PCI or CABG &lt;3 months

        -  Heart transplant

        -  Placement of septal RV electrode is not possible

      Study design:

        -  Prospective, monocentric, randomized, double-blinded

        -  Run-in phase: 4 weeks AAI [R]-DDD [R]

        -  ECG, PM-interrogation, echocardiography, performance diagnostics, CPX, QoL questionnaire

        -  Randomization: two groups 4 weeks (between 3 to 6 weeks) after implant A) septal right
           ventricular chamber pacing: mode DDD [R] versus B) Reduction of unnecessary ventricular
           pacing: AAI [R]-DDD [R].

        -  FU: 6 and 12-months

        -  ECG, Holter-ECG, PM-interrogation, echocardiography, performance diagnostics, CPX, QoL
           questionnaire

        -  Extension of follow-up if possible

      Primary endpoints:

      -LV ejection fraction and end-systolic LV volume after 12 months.

      Secondary endpoints:

      -LV end-diastolic volume, TAPSE, parameters of dyssynchrony (SPWMD, LV-PEP, IVMD), AF-burden,
      % ventricular pacing, CPX: peak oxygen consumption (peak VO2), VO2 AT, VO2/HR, VE/VCO2 slope;
      QoL scores (SF-36) after 12 months.

      Blinding:

        -  Patient compared to the pacing mode

        -  Physician: offline analysis of echo and CPX blinded to the pacing mode

      Statistics/sample size estimation:

      In order to detect a difference in LVEF of 5% and for LV-ESV of 5 mL between the 2 groups
      after 12 months:

        -  90% power/alpha 5%: 84 patients per group

        -  80% power/alpha 5%: 63 patients per group

             -  10% for compensation of drop-outs / patients lost of follow-up. Two-sided 5% type 1
                error Analysis intention-to-treat and based on the finally programmed pacing mode.

      Material

        -  PG: market released dual chamber pacemakers with the ability to pace AAI(R) -DDD(R)

        -  pacing leads: market-released standard active electrodes (eg. BSCI FineLine 4470 and
           4471) Implantation

        -  Transvenously

        -  RA-electrode: if possible, short atrial conduction time

        -  RV electrode: septal verified under multi-level screening (RAO/LAO) and ECG (LBBB narrow
           &lt;150 ms / inferior axis)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>end-systolic LV volume</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular ejection fraction (LV-EF)</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
    <description>TTE, Simpson, biplane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TAPSE</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic parameter of dyssynchrony</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
    <description>TTE, SPWMD, LV-PEP, IVMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak VO2, VO2 AT, VO2/HR, VE/VCO2 slope</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
    <description>CPX: cardiopulmonary exercice testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life-scores</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% ventricular pacing</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV end diastolic volume</measure>
    <time_frame>at randomisation and after 12 months</time_frame>
    <description>TTE</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Sick Sinus Syndrome</condition>
  <arm_group>
    <arm_group_label>DDD(R)</arm_group_label>
    <description>SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAI(R)&lt;=&gt;DDD(R)</arm_group_label>
    <description>SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)</intervention_name>
    <description>Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.</description>
    <arm_group_label>DDD(R)</arm_group_label>
    <arm_group_label>AAI(R)&lt;=&gt;DDD(R)</arm_group_label>
    <other_name>AAI(R)&lt;=&gt;DDD(R)</other_name>
    <other_name>DDD(R)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with symptomathic sick sinus syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pacemaker indication according to current guidelines: sick sinus syndrome (SSS)

        Exclusion Criteria:

          -  Life expectancy &lt;2 years

          -  Age &lt; 18 years

          -  Noncompliance with regard to participation in the study

          -  Pregnancy

          -  AV block ° 2 and higher

          -  Permanent atrial fibrillation

          -  Heart failure NYHA III and IV, reduced LV-EF &lt; 40%

          -  ICD indication

          -  Acute coronary syndrome. PCI or CABG &lt; 3 months

          -  Heart transplant

          -  Placement of septal RV electrode is not possible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Pauschinger, Prof.Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Nuernberg South/ Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Bastian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nuernberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Bastian, Dr.med</last_name>
    <phone>+499113982989</phone>
    <email>dirk.bastian@klinikum-nuernberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Rohr</last_name>
    <email>natalia.rohr@klinikum-nuernberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Nuernberg South</name>
      <address>
        <city>Nuernberg</city>
        <state>Bavaria</state>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bastian</last_name>
      <email>dirk.bastian@klinikum-nuernberg.de</email>
    </contact>
    <investigator>
      <last_name>Natalia Rohr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Kirste, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schwaab B, Fröhlig G, Alexander C, Kindermann M, Hellwig N, Schwerdt H, Kirsch CM, Schieffer H. Influence of right ventricular stimulation site on left ventricular function in atrial synchronous ventricular pacing. J Am Coll Cardiol. 1999 Feb;33(2):317-23.</citation>
    <PMID>9973009</PMID>
  </reference>
  <reference>
    <citation>Tse HF, Yu C, Wong KK, Tsang V, Leung YL, Ho WY, Lau CP. Functional abnormalities in patients with permanent right ventricular pacing: the effect of sites of electrical stimulation. J Am Coll Cardiol. 2002 Oct 16;40(8):1451-8.</citation>
    <PMID>12392836</PMID>
  </reference>
  <reference>
    <citation>Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA; MOde Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003 Jun 17;107(23):2932-7. Epub 2003 Jun 2.</citation>
    <PMID>12782566</PMID>
  </reference>
  <reference>
    <citation>Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002 Dec 25;288(24):3115-23.</citation>
    <PMID>12495391</PMID>
  </reference>
  <reference>
    <citation>Stambler BS, Ellenbogen K, Zhang X, Porter TR, Xie F, Malik R, Small R, Burke M, Kaplan A, Nair L, Belz M, Fuenzalida C, Gold M, Love C, Sharma A, Silverman R, Sogade F, Van Natta B, Wilkoff BL; ROVA Investigators. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol. 2003 Nov;14(11):1180-6.</citation>
    <PMID>14678131</PMID>
  </reference>
  <reference>
    <citation>Giudici MC, Thornburg GA, Buck DL, Coyne EP, Walton MC, Paul DL, Sutton J. Comparison of right ventricular outflow tract and apical lead permanent pacing on cardiac output. Am J Cardiol. 1997 Jan 15;79(2):209-12.</citation>
    <PMID>9193029</PMID>
  </reference>
  <reference>
    <citation>de Cock CC, Meyer A, Kamp O, Visser CA. Hemodynamic benefits of right ventricular outflow tract pacing: comparison with right ventricular apex pacing. Pacing Clin Electrophysiol. 1998 Mar;21(3):536-41.</citation>
    <PMID>9558684</PMID>
  </reference>
  <reference>
    <citation>Alboni P, Scarfò S, Fucà G, Mele D, Dinelli M, Paparella N. Short-term hemodynamic effects of DDD pacing from ventricular apex, right ventricular outflow tract and proximal septum. G Ital Cardiol. 1998 Mar;28(3):237-41.</citation>
    <PMID>9561877</PMID>
  </reference>
  <reference>
    <citation>Yu CM, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, Fang F, Lam KH, Chan HC, Fung JW. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009 Nov 26;361(22):2123-34. doi: 10.1056/NEJMoa0907555. Epub 2009 Nov 15.</citation>
    <PMID>19915220</PMID>
  </reference>
  <results_reference>
    <citation>Nielsen, Jens Cosedis - Blomstrom-Lundqvist, Carina. DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome. ESC Kongress 2010, Stockholm, Session number: 708001 - 70800.</citation>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Nürnberg</investigator_affiliation>
    <investigator_full_name>Natalia Rohr</investigator_full_name>
    <investigator_title>Natalia Rohr</investigator_title>
  </responsible_party>
  <keyword>Sick Sinus Syndrome</keyword>
  <keyword>Cardiac Pacing, Artificial</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>Pacemaker, Artificial</keyword>
  <keyword>SSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sick Sinus Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

